The Competition Appeal Tribunal has granted the first public sector collective proceedings order (CPO), with the Home Office ...

Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC.

Learn how a nutraceutical brand is investing in responsible and transparent manufacturing.

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the ...

LONDON, GREATER LONDON, UNITED KINGDOM, October 20, 2025 /EINPresswire.com/ -- Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry ...

BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...

“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

The Flexible Packaging Association and other business groups want President Donald Trump's administration to intervene in ...

BRS working president KT Rama Rao said research must serve the common man, calling it futile otherwise. Inaugurating Huwel’s ...

Hundreds of kilometres from the nearest supermarket, Indigenous rangers in Australia's remote north are working to keep eggs ...